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The Application of Enamel Matrix
Protein Derivative (Emdogain®) 
in Regenerative Periodontal
Therapy: Which Applications are
Evidence-Based?
Summary
The goal of regenerative periodontal therapy is the reconstitution of
the lost periodontal structures (i.e. the new formation of root cemen-
tum, periodontal ligament and alveolar bone). Results from basic
research have pointed to the important role of the enamel matrix pro-
tein derivative (EMD) in periodontal wound healing. Histological results
of experiments in animals and of human case reports have shown that
treatment with EMD promotes periodontal regeneration. Moreover,
clinical studies have indicated that treatment with EMD positively influ-
ences periodontal wound healing in humans. The goal of the current
overview is to present, based on the existing evidence, the clinical indi-
cations for regenerative therapy with EMD. 
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Results from basic research have indicated the
role of the different types of cementum for attach-
ing the tooth and for the reparative processes in the
entire periodontium. Acellular cementum is the most
important tissue for the insertion of collagen fibres
(1) and plays thereby the largest role in attaching the
tooth to the alveolar socket. Studies of SLAVKIN
and BOYDE (2) and SLAVKIN (3) show that pro-
teins, which are secreted during the tooth develop-
ment by the Hertwig’s root sheath, play a crucial
role in the formation of acellular root cementum.
These proteins, referred to as enamel matrix pro-
teins, constitute the largest part of the enamel matrix
(1, 4). They consist of a whole family of proteins,
from which 90 % are Amelogenin, and the remain-
ing 10% consist of prolin-rich non-Amelogenins,
Tuftelin, and other serum proteins (1). It has been
shown that the chemical structure of Amelogenin
remained more or less constant during evolution,
even among the individual animal species, exhibit-
ing only slight differences (5). In a series of animal
experiments on root development in rats, monkeys
and pigs, it was immunohistologically demonstrat-
ed that the concentration of Amelogenin rises dra-
matically during tooth development (1). In addition
a close connection between acellular cementum and
amelogenin exists (1). These results have also been
confirmed in investigations of human teeth, where-
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by some histological sections showed a thin layer of
highly-mineralized enamel between dentin and root
cement. This observation permits the assumption
that the attachment of enamel matrix must occur
on the dentin surface before the emergence of acel-
lular cementum (1). Based on these results several
in vivo experiments in animal models were conduct-
ed (1). In an experiment the lateral incisors of two
monkeys were extracted. Immediately after the
extraction a standardized cavity in the root surface
was created mesially and distally. The test cavities
were then filled with an enamel matrix derivative,
while the control cavities remained untreated. All
teeth were reimplanted into their original alveoles.
Histological evaluation eight weeks after reimplanta-
tion resulted in formation of acellular cementum in
the defects in which enamel matrix derivative was
applied; whereas in the untreated control defects
only a reparative, cellular cementum developed (1).
On the basis of these findings the enamel matrix
derivative (EMD) from the tooth pouches of non-
-erupted teeth from young pigs were isolated, puri-
fied and lyophylisated. Since EMD are extreme
hydrophobic, they were brought by means of a
propylene glycol alginate (PGA) carrier into solu-
ble form before their use in regenerative periodon-
tal therapy (1). A technique or a material must, how-
ever, fulfill the following criteria in order to be clas-
sified as “regeneration-promoting” (6):
1. In vitro studies, which confirm the action mech-
anism. 
2. Controlled histological animal studies, which
demonstrate formation of new root cementum,
periodontal ligament and alveolar bone. 
3. Human biopsies, which show formation of root
cementum, periodontal ligament and alveolar
bone on a plaque-infected root surface.
4. Controlled clinical studies, which prove gain of
clinical attachment and radiological new bone
formation. In the following overview, the existing
evidence regarding the clinical use of EMD is
provided. 
In-vitro studies
Several in vitro investigations were carried out
to study the mechanism of the EMD on the desmod-
ontal gingival and bone cells (7-17).Thus in a series
of laboratory studies the migration, attaching, pro-
liferation, biosynthesis activity and formation of
mineralized nodules following the application of
EMD were examined. To determine the possible
presence of existing polypeptide factors immunoas-
says were performed (8, 9). The results have shown
that: a) under in vitro conditions EMD promotes the
proliferation of periodontal ligament fibroblasts, but
not that of epithelial cells, b) the total protein syn-
thesis of the periodontal ligament fibroblasts increas-
es, and c) the formation of mineralized nodules by
periodontal ligament fibroblasts is promoted. 
Furthermore, no specific polypeptid factors such
as IGF-1,2; PDGF, TNNF, TGFβ, or IL-1β could
be identified. In further investigations it was shown
that the attaching growth and metabolic rate of
desmodontal fibroblasts increased significantly,
when EMD was added in cell cultures (8-11, 13).
Moreover, periodontal ligament fibroblasts treated
with EMD displayed an increased intracellular
cAMP concentration and autocrine releasing of
TGF-1β, IL-6 and PDGF in comparison to the con-
trol group (without addition of EMD) (13). Although
the epithelial cells showed an increased release of
cAMP and PDGF following the additional applica-
tion of EMD, their proliferation and growth rate was
inhibited (11, 13). It was concluded that EMD simul-
taneously promotes the growth of mesenchymal cells
by inhibiting that of the epithelial cells. It was also
concluded that EMD promotes the release of
autocrine growth factors from desmodontal fibrob-
lasts (13). Furthermore, desmodontal fibroblasts
showed a significantly increased alkaline phos-
phatase activity following the application of EMD
(17). Very recent investigations have demonstrated
that EMD significantly increased the mRNA syn-
thesis of the matrix proteins Versican, Byglycan and
Decorin and led to an increased Hyaluronan syn-
thesis in the gingival and desmodontal fibroblasts
(10). However, it has to be emphasized that in all
studies EMD had a much stronger effect on the
desmodontal fibroblasts than on gingival fibroblasts.
Further experimental investigations have shown that
the application of EMD can regulate the expression
of the genes associated with cementoblasts which in
turn affects crucially the mineralization process (16).
Kawase et al. (18) examined the effect of EMD on
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the proliferation of oral epithelium cells (SCC25).
After 3 days of treatment with EMD the cell divi-
sion was prevented and at the same time the cell
cycle was stopped in the G1 phase. Additionally, it
was shown that the addition of EMD limited sig-
nificantly the expression of Cytokeratin-18 (CK18).
The authors concluded that EMD does not possess
a cytostatic but rather, a cytotoxic effect on epithe-
lial cells (18). In an in vitro study the combination
of 4 mg EMD and active demineralized freeze-dried
allogenic bone (DFDBA) showed an increased bone
induction (7). It was concluded that EMD possess-
es no osseoinductive, but rather osteopromotive
characteristics when applied in certain concentra-
tions (7). Schwartz et al. (15) have shown that EMD
stimulates the early stages of the osseoblast matu-
ration by increasing cell proliferation. However,
when applied on mature cell lines, the main effect
was confined to the influence of cell differentiation.
Recently, certain antibacterial effects and distur-
bances of bacterial adherence were found to be influ-
enced by EMD (19-22). After 4 days of plaque accu-
mulation a plaque sample was taken from 24 patients
with chronic periodontitis and divided into 5 equal
parts (21). Each part was mixed with 5 μl of the
following solutions: 1) NaCl, 2) EMD solved in
water, 3) EMD solved in PGA vehicle, 4) PGA vehi-
cle, 5) Chlorhexidine digluconate (CHX). Subse-
quently, the vitality of the plaque flora was evalu-
ated under the vital fluorescent microscope. The
results have shown that EMD solved in the PGA
vehicle had a very strong antibacterial effect. It was
concluded that the antibacterial effect of EMD is
mainly due to the effect of the PGA carrier. In a fur-
ther investigation it was shown that EMD inhibits
the growth of the periodontal pathogenic bacteria
Actinobacillus actinomycetemcomitans, Porphy-
romonas gingivalis and Prevotella intermedia. 24
hours following the application of EMD no living
colonies of these pathogenic bacterias could be
observed. Moreover, EMD demonstrated no nega-
tive effect on gram positive bacteria (22). The
inhibiting effect of EMD on periodontal pathogen-
ic bacteria was also confirmed by others (20).
In conclusion the data from in vitro studies indi-
cate that EMD affects important wound healing
mechanisms. 
Controlled histological studies in animals
In a controlled histological study, recession
defects were created and treated with EMD (23).
Standardized defects were created, by surgically
removing the entire buccal bone plate and the root
cementum. The test defects were treated with EMD,
while in the control defects a coronally repositioned
flap was made. Eight weeks after surgery the ani-
mals were sacrificed and the appropriate jaw seg-
ments histologically evaluated. The results have
shown that in all test defects a new periodontium,
i.e. acellular cementum with inserting collagen fibers
and new alveolar bone developed. In the control
defects, the healing was characterized by a long junc-
tional epithelium with very limited cementum and
new bone formation. If in the control defects new
cementum was formed, it was mostly more acellu-
lar and only partly attached at the root surface. An
interesting aspect of this study is that in the test
defects no root resorption occurred, while in the con-
trol defects the root resorption was a very frequent-
ly found phenomenon. It is important to mention that
during the entire study period no oral hygiene meas-
ures were carried out. In two further studies in mon-
keys, intrabony defects were created surgically (24,
25). The defects were treated with one of the fol-
lowing therapies: a) Guided Tissue Regeneration
(GTR), b) EMD, c) EMD + GTR or d) with con-
ventional flap debridement surgery (control). The
histological investigation has shown that the heal-
ing was characterized by a long junctional epitheli-
um and a limited periodontal regeneration after flap
debridement surgery. The treatment with GTR,
EMD and EMD + GTR resulted in formation of
cementum with inserting collagen fibres as well as
of alveolar bone (24, 25).
Results from human histological studies
Results of the first human-histological biopsy
were published by Heijl (26). A recession defect
on a lower incisor, was surgically created and treat-
ed with EMD. After a healing period of 4 months,
the tooth as well as the surrounding soft and hard
tissue was extracted and histologically evaluated.
The histological investigation showed that a new
layer of acellular root cementum covered 73% of the
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original defect depth. New alveolar bone had regen-
erated on 65% of the initial bone height. In anoth-
er study Yukna and Mellonig (27) treated 10 intra-
bony periodontal defects in 8 patients with EMD.
The histological analysis 6 months after the treat-
ment showed in 3 biopsies complete periodontal
regeneration (i.e. new formation of root cementum,
periodontal ligament and alveolar bone), while in 3
further biopsies, the healing was characterized by a
new connective tissue attachment (i.e. new cemen-
tum with inserting collagen fibers). Four biopsies
healed by a long junctional epithelium and without
any signs of periodontal regeneration. In a compar-
ative clinical and histological investigation the heal-
ing of intrabony periodontal defects was evaluated
following treatment with EMD or Guided Tissue
Regeneration (GTR) with a bioabsorbable barrier
(28). Six months after therapy, the clinical attach-
ment level (CAL) showed a mean gain of 3.2 ± 1.2
mm in the EMD group and of 3.6 ± 1.7 mm in the
GTR group. The histological analysis showed that
in both groups the healing was mainly characterized
by periodontal regeneration (28). The mean value
of new cementum and periodontal ligament amount-
ed to 2.6 ± 1.0 mm in the EMD group and to 2.1 ±
1.0 mm in the GTR group. The mean value of new
alveolar bone was 0.9 ± 1.0 mm in the EMD group
and of in the GTR group 2.1 ± 1.0 mm. Reparative
healing by a long junctional epithelium occurred
only in one biopsy from the EMD group. The results
of the study have confirmed that treatment with
EMD promotes periodontal regeneration in humans
and may lead to comparable clinical and histologi-
cal results than the GTR therapy. These results were
confirmed in subsequent reports by other authors,
not only in intrabony but also in recession-type
defects (29-32). Very recent immunohistological
studies in human have also shown that EMD remains
up to 4 weeks following surgery on the root sur-
face and, that the wound healing and/or remodelling
process can be followed for a period of up to 6
months after treatment with EMD therapy (33, 34).
However, no periodontal regeneration was observed,
when EMD was applied in a non-surgical way into
the periodontal defects (35).
Controlled clinical studies
Side effects, such as for example incompatibili-
ty or allergic reactions even after repeated treatment
with EMD, were not reported in any published stud-
ies (36-38). Data from controlled clinical studies
have demonstrated that treatment of intrabony
defects with EMD results in a significant reduction
of the probing depths and gain of clinical attach-
ment. A randomized, placebo controlled multicen-
ter-study examined the effectiveness of EMD in the
split-mouth procedure in 33 patients (39). The results
after 36 months showed a mean CAL gain of 2.2
mm in the test group and of 1.7 mm in the control
group (open flap debridement). The radiologically
determined bone gain amounted to 2.6 mm in the
test group, with a 66% fill of the bone defects. How-
ever, the control teeth did not show any bone gain.
In another controlled clinical study Froum et al. (40)
compared the treatment of deep intrabony defects
by open flap surgery with and without EMD. In 23
patients with at least 2 intrabony defects each a total
of 53 defects were treated with open flap surgery +
EMD and 31 were treated with open flap surgery
alone. After a healing phase of 12 months the defects
were again opened and the defect fill measured. The
results showed that the treatment with open flap sur-
gery + EMD resulted in a 3 x larger defect fill than
the treatment with flap surgery alone (74% defect
fill after flap surgery + EMD vs. 23% defect fill after
flap surgery alone) (40). In a further prospective,
controlled clinical study a total of 40 patients were
treated by surgical therapy with either EMD or GTR
with a non-bioabsorbable or with 2 bioabsorbable
barriers and compared to the open flap surgery (con-
trol) (41). All 4 regenerative procedures were equal-
ly effective regarding probing depth (PD) reduc-
tion and CAL gain and were, significantly better than
the control treatment. A prospective, randomized,
multi-center clinical study reported the treatment
of intrabony defects with the papilla preservation
technique with and without auxiliary application of
EMD (42). A total of 83 test and 83 control defects
were treated. After one year the results showed sig-
nificantly higher CAL gain in the test group than
in the control group (42). Comparative studies
reported comparable results after treatment of intra-
bony defects with EMD or GTR, whereby the type
of the GTR barrier (not bioabsorbable or bioab-
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sorbable) did not play a role (41, 43-45). In a
prospective, controlled, clinical study the treatment
of intrabony defects was evaluated following treat-
ment with EMD, GTR, combination of EMD + GTR
and open flap surgery (44). The results have shown
that all 3 regenerative procedures resulted in a sig-
nificantly higher improvement of the clinical param-
eters compared to the conventional flap surgery;
whereby the combination of EMD + GTR led to no
additional improvement. The data from controlled
clinical studies generally show that the additional
application of EMD in the context of surgical ther-
apy of deep intrabony periodontal defects may lead
to stastically significantly better clinical results com-
pared to open flap debridement (39, 41, 42, 44-47).
The clinical results are comparable to those after
GTR therapy. Very recent data have also shown that
the clinical results after treatment of intrabony
defects with EMD can be maintained over a longer
time period (4 and/or 5 years) (48-50).
Combination therapies
Experimental and clinical studies have indicated
that the extent of the regeneration is determined by
the available space under the mucoperiostal flap (28,
51). A collapse of the mucoperiostal flap may limit
the area needed for the regeneration process and may
thus affect the result of the therapy. In order to avoid
these disadvantages, combination therapies between
EMD and GTR and/or EMD and bone substitutes
were tested. Observations from animal-histological
and human-histological studies have demonstrated
periodontal regeneration after treatment of intrabony
defects with some of these combinations. Data from
controlled clinical studies are controversial and no
clear advantage of a combination therapy in relation
to the single therapies has been proven EMD (24,
25, 44, 52-58). 
Treatment of recession defects
Histological results from animals and humans
have shown that treatment of buccal recession
defects with a coronally positioned flap and EMD
can result not only in a covering of the gingival
recession but also in the formation of cementum,
periodontal ligament and bone (23, 24, 26, 29, 31).
In two controlled clinical studies the treatment of
buccal Miller class I and II gingival recessions with
a coronally positioned flap and EMD or coronally
positioned flap were examined using the split-mouth
procedure (59, 60). The results did not show dif-
ferences between the therapies concerning root cov-
erage. The additional application of EMD led, how-
ever, to statistically significantly higher formation
of keratinized tissue than the coronally positioned
flap technique alone (59). In a recently published
controlled, clinical, split-mouth study involving 17
patients the therapy of buccal Miller class II reces-
sions with a coronally positioned flap and EMD (test
group) or with a coronally positioned flap and con-
nective tissue graft (control) was compared (61). The
results have shown that one year after therapy the
mean value of root coverage was 95.1% in the test
group and 93.8% in the control group. A 100% root
coverage was reached in 89.5% of the cases in the
test group and in 79% of the cases in the control
group. The additional histological evaluation of two
biopsies showed that treatment of recession defects
with a coronally positioned flap and EMD resulted
in formation of root cementum, periodontal ligament
and alveolar bone, while treatment with a coronal-
ly positioned flap and a connective graft was char-
acterized by a long junctional epithelium and even
signs of root resorption (29). 
Treatment of furcation defects
Histological results from studies in monkeys have
indicated that the treatment of class III mandibular
furcation defects with EMD results in no predictable
periodontal regeneration (62). At present there are
no human-histological data regarding the healing of
furcation defects following treatment with EMD.
Data from controlled clinical studies evaluating the
treatment of furcation defects by means of flap sur-
gery with and without EMD are also lacking. A
multi-center, randomized, controlled, split-mouth,
clinical study compared the treatment of mandibu-
lar class II furcation defects with EMD or GTR (63).
The results have indicated that the treatment with
EMD resulted in significantly higher CAL gain and
bone fill than the GTR therapy
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Conclusions
Based on the presented evidence the following
conclusions can be drawn: 
a. Surgical periodontal treatment of deep intrabony
defects with EMD promotes periodontal regen-
eration. The application of EMD in the context
of non-surgical periodontal therapy has failed
to result in periodontal regeneration. 
b. Surgical periodontal therapy of deep intrabony
defects with EMD may lead to significantly high-
er improvements of the clinical parameters than
open flap debridement alone. The results obtained
following treatment with EMD are comparable
to those following treatment with GTR. 
c. For the time being there is no clear evidence of
an advantage of a combination of therapies, such
as EMD and GTR or EMD and bone substitutes,
in relation to single therapies.
